Clinical Trials Logo

CMML clinical trials

View clinical trials related to CMML.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05153226 Recruiting - AML Clinical Trials

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

GRAPPA
Start date: March 2, 2022
Phase: Phase 3
Study type: Interventional

Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly conducted with ATG. Still, the burden of acute and chronic GVHD and especially of relapse remains high with both approaches for GVHD prevention. PTCY has not been tested against the current standard ATG for GvHD prophylaxis in large randomized trials. The goal of this trial is to compare the outcomes of PTCY and ATG for patients receiving unrelated donor PBSCT. PTCY-based prophylaxis promises to have beneficial net effects on immune reconstitution, GVHD and disease control, and thus might impact on patient survival.

NCT ID: NCT04730258 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

TWT-202
Start date: April 16, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

NCT ID: NCT04372433 Recruiting - CMML Clinical Trials

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

NCT ID: NCT04358393 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Start date: December 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.